$10.75 Million in Sales Expected for Avid Bioservices Inc (CDMO) This Quarter

Brokerages expect Avid Bioservices Inc (NASDAQ:CDMO) to post sales of $10.75 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Avid Bioservices’ earnings, with the lowest sales estimate coming in at $8.00 million and the highest estimate coming in at $13.50 million. Avid Bioservices posted sales of $12.78 million in the same quarter last year, which suggests a negative year over year growth rate of 15.9%. The firm is scheduled to announce its next earnings results on Monday, December 10th.

On average, analysts expect that Avid Bioservices will report full year sales of $54.60 million for the current financial year, with estimates ranging from $54.20 million to $55.00 million. For the next financial year, analysts anticipate that the firm will post sales of $69.70 million, with estimates ranging from $67.40 million to $72.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Avid Bioservices.

Avid Bioservices (NASDAQ:CDMO) last posted its quarterly earnings results on Monday, September 10th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.03. The business had revenue of $12.59 million during the quarter, compared to the consensus estimate of $9.95 million. Avid Bioservices had a negative return on equity of 60.06% and a negative net margin of 57.67%.

A number of equities analysts recently commented on the company. ValuEngine downgraded Avid Bioservices from a “buy” rating to a “hold” rating in a research note on Monday, October 8th. HC Wainwright lifted their price target on Avid Bioservices from $6.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, September 11th. Finally, Zacks Investment Research downgraded Avid Bioservices from a “hold” rating to a “sell” rating in a research note on Thursday, July 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Avid Bioservices currently has an average rating of “Buy” and a consensus target price of $8.33.

In other Avid Bioservices news, Director Joel Mccomb sold 50,000 shares of Avid Bioservices stock in a transaction that occurred on Thursday, September 20th. The stock was sold at an average price of $6.53, for a total value of $326,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.92% of the company’s stock.

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. boosted its stake in Avid Bioservices by 9.7% in the third quarter. BlackRock Inc. now owns 3,576,949 shares of the biopharmaceutical company’s stock valued at $24,538,000 after acquiring an additional 315,661 shares during the period. Bank of New York Mellon Corp boosted its stake in Avid Bioservices by 19.6% in the third quarter. Bank of New York Mellon Corp now owns 154,883 shares of the biopharmaceutical company’s stock valued at $1,062,000 after acquiring an additional 25,361 shares during the period. Granite Investment Partners LLC acquired a new position in Avid Bioservices in the third quarter valued at approximately $572,000. EAM Global Investors LLC acquired a new position in Avid Bioservices in the third quarter valued at approximately $1,404,000. Finally, EAM Investors LLC acquired a new position in Avid Bioservices in the third quarter valued at approximately $2,023,000. Institutional investors own 21.79% of the company’s stock.

NASDAQ:CDMO traded down $0.28 during mid-day trading on Monday, reaching $5.02. The stock had a trading volume of 335,860 shares, compared to its average volume of 235,337. The company has a market capitalization of $299.61 million, a price-to-earnings ratio of -10.04 and a beta of 2.61. Avid Bioservices has a 1-year low of $2.24 and a 1-year high of $8.44.

About Avid Bioservices

Avid Bioservices, Inc, a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

See Also: Do You Need a Fiduciary?

Get a free copy of the Zacks research report on Avid Bioservices (CDMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Avid Bioservices (NASDAQ:CDMO)

Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply